Aortech International (AOR)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.25 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Mar | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | -7.2% | |||||||||
FINANCIAL BRIEF: For the six months ended 30 September 2012, AorTech International plc revenues decreased 69% to $822K. Net loss totaled $1.5M vs. income of $284K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Australia segment loss totaling $71K vs. income of $1.7M, United States segment loss increase of 53% to $977K, United Kingdom segment loss increase of 3% to $461K. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
AorTech International plc is a holding company. The Company is engaged in the development and exploitation of a range of biomaterials and medical devices. The Company’s segments are based on geographical location of operations, which includes United Kingdom, Australia and United States. The Company’s polymer technology includes Elast-Eon, ECSil and E- RIM. AorTech is based in Rogers, Minnesota, where its principal manufacturing and research and development facility is located. The Company’s subsidiaries include AorTech Biomaterials Limited, AorTech Critical Care Limited, AorTech Heart Valve Technologies Limited, AorTech Biomaterials Pty Limited AorTech Polymers & Medical Devices, Inc. and River Clyde Marine, Inc.
Directors: Frank Maguire (CEO) , Edward McDaid (Fin. Dir.) , J. C. David Parsons (Secy.) ,
No. of Employees: 25 No. of Shareholders: n/a
| Last Annual | March 31st, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 4,832,778 |
| Free Float | 2.69m (55.6%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Level Two,Springfield House 23 Oatlands Drive, 81-83 Victoria Road Surbiton, WEYBRIDGE, KT13 9LZ, United Kingdom |
| Web | http://www.aortech.com |
| Phone | +44 1932 252123 |
| Contact | () |
| Registrar | Lloyds TSB Registrars (Edinburgh - Orchard Brae) |
| Auditors | Grant Thornton UK LLP |
| 20th Mar | Commencement of legal proceedings |
| 27th Dec '12 | Half Yearly Report |
| 24th Dec '12 | Dispute with St Jude Medical resolved |
| 5th Nov '12 | Update re litigation |
| 26th Oct '12 | Issue of loan notes |
| 22nd Oct '12 | Update |
Recent ↓
